Effect of HCCD Supplemented With Omega-3 Fatty-Acids on Inflammation in Healthy, Overweight Subjects (HCCD)
Primary Purpose
Inflammation
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
omega-3 fatty acids
high complex carbohydrate diet
Sponsored by
About this trial
This is an interventional prevention trial for Inflammation focused on measuring Inflammation, carbohydrates, omega-3, overweight, diet
Eligibility Criteria
Inclusion Criteria:
- 150 healthy overweight volunteers
Exclusion Criteria:
- Individuals who had an infective/inflammatory disease during the six month period prior to the commencement of the study, and individuals who are on treatment with statins or any steroidal or non steroidal anti inflammatory agents, except for aspirin at a dose of up to 325 mg/day, will be excluded.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
1
2
Arm Description
8-weeks of high complex carbohydrate diet
omega-3 fatty acids supplements
Outcomes
Primary Outcome Measures
markers of inflammation
Secondary Outcome Measures
difference in the pattern of monocyte gene expression
Full Information
NCT ID
NCT00504478
First Posted
July 19, 2007
Last Updated
July 19, 2007
Sponsor
Tel-Aviv Sourasky Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00504478
Brief Title
Effect of HCCD Supplemented With Omega-3 Fatty-Acids on Inflammation in Healthy, Overweight Subjects
Acronym
HCCD
Study Type
Interventional
2. Study Status
Record Verification Date
April 2007
Overall Recruitment Status
Unknown status
Study Start Date
January 2008 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Tel-Aviv Sourasky Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to examine the anti inflammatory effect of high complex carbohydrate diet, supplemented by omega-3 fatty acids.
Detailed Description
Background: Atherosclerosis is the main cause for premature morbidity and mortality in the western world. It becomes evident that one of the main causes for development of atherosclerosis is the presence of low grade, internal inflammation. The inflammatory process leads to endothelial dysfunction, the early event in the pathogenesis of atherosclerosis. The inflammatory process is known to be induced by several factors such as obesity, recurring infections, smoking, and sedentary lifestyle. It was found that weight reduction decreased sub clinical inflammation. It was also found that the composition of the diet affects the inflammatory process.
Working hypothesis and aims: Our preliminary results show that high complex carbohydrate diet (HCCD) has beneficial effect on several markers of inflammation. The aims of this study are to reinforce our preliminary results by measuring the effect of HCCD on additional markers of inflammation (TNFα, IL6) and of endothelial dysfunction (ICAM-1, VCAM-1), and to identify the genes affected by HCCD in monocytes. In addition the aim of this study is to determine whether consumption of omega-3 oil actually increase the anti-inflammatory effect obtained by HCCD.
Methods: 150 healthy overweight volunteers will be divided into 2 groups; HCCD group and HCCD supplemented with the omega-3 fatty acids. Blood sample will be taken following an overnight 12 hour fast, before and after 8 weeks diet, for the following analysis: total cell count, plasma lipids, glucose and insulin, erythrocyte sedimentation rate, fibrinogen, white blood cell count, and CRP. Markers of leukocyte activation will be determined using FACS analysis. In addition, using ELISA, the following pro and anti inflammatory cytokines and markers for endothelial dysfunction will be analyzed: VCAM-1 and ICAM-1. Micro array analysis for genes transcription differences induced by HCCD will be performed in monocytes using Affymetrix chips.
Expected results: We assume that HCCD consumption may improve the inflammatory markers as well as markers of endothelial dysfunction and affect expression of genes involved in inflammation in monocytes. In addition we assume that omega-3 fatty acids will strengthen the positive effect of HCCD on parameters of inflammation.
Importance and probable implications to Medicine: The results of this study may establish scientific basis for guiding people for healthy lifestyle, including the consumption of diet composed of components with anti inflammatory effects, as well as nutritional supplements enhancing anti-inflammatory properties of the diet. This work will also be able to establish the influence of the diet and supplementations on gene expression for inflammatory reaction in monocytes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammation
Keywords
Inflammation, carbohydrates, omega-3, overweight, diet
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
8-weeks of high complex carbohydrate diet
Arm Title
2
Arm Type
Experimental
Arm Description
omega-3 fatty acids supplements
Intervention Type
Dietary Supplement
Intervention Name(s)
omega-3 fatty acids
Intervention Description
omega-3 supplement will be given in addition to high complex carbohydrate diet.
Intervention Type
Other
Intervention Name(s)
high complex carbohydrate diet
Primary Outcome Measure Information:
Title
markers of inflammation
Time Frame
2 years
Secondary Outcome Measure Information:
Title
difference in the pattern of monocyte gene expression
Time Frame
1 year
10. Eligibility
Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
150 healthy overweight volunteers
Exclusion Criteria:
Individuals who had an infective/inflammatory disease during the six month period prior to the commencement of the study, and individuals who are on treatment with statins or any steroidal or non steroidal anti inflammatory agents, except for aspirin at a dose of up to 325 mg/day, will be excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shlomo Berliner, MD PhD
Phone
972-3-6974961
Email
berliners@tasmc.health.gov.il
First Name & Middle Initial & Last Name or Official Title & Degree
Olga Raz
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shlomo Berliner, MD PhD
Organizational Affiliation
The Tel Aviv Sauraski Medical Center
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effect of HCCD Supplemented With Omega-3 Fatty-Acids on Inflammation in Healthy, Overweight Subjects
We'll reach out to this number within 24 hrs